Phaseline

Companies › Q32 Bio

Q32 Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
bempikibart (ADX-914)
IKZF3 degrader (molecular glue)
IKZF3Phase 2Atopic Dermatitis; Alopecia Areata–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05509023bempikibart (ADX-914)Phase 2Atopic DermatitisImmunologyDec 2024
NCT06018428bempikibart (ADX-914)Phase 2Alopecia AreataImmunologyJun 2026

From the company's SEC filings

Cash of $290m on 2026-09-30; operating cash outflow about $19m a year; runway about 187 months at that burn, to Apr 2042

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IKZF3 (1)

Companies with the same targets

Bristol-Myers Squibb

Companies built like this

AnaptysBio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Zura Bio Chengdu Kangnuoxing Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.